Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM)

Cancer Biology and Therapy

Volumn 10, Issue 6, 2010, Pages 582-587

  Carter, Hannah ^a   Samayoa, Josue ^a   Hruban, Ralph H ^b,c   Karchin, Rachel ^a  

^a Institute for Computational Medicine ^*  (United States)

^b Department of Oncology ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer drivers; CHASM; Missense mutations; Pancreatic cancer; Somatic mutations

Indexed keywords

CALCIUM BINDING PROTEIN; DIACYLGLYCEROL KINASE; PROTEIN KINASE C GAMMA; PROTEIN SERINE KINASE; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CELL ADHESION; CELL CYCLE; GENETIC ANALYSIS; MISSENSE MUTATION; PANCREAS CANCER; SOMATIC MUTATION;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PANCREATIC NEOPLASMS; SMAD4 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957154710     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.6.12537     Document Type: Article

References (54)

1. Society AC. Cancer Facts and Figures 2009. Atlanta: American Cancer Society, Inc. 2009.
2. Jones S, Zhang Z, Parsons DW, Lin J, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancer revealed by tumor genome analysis. Science 2008; 321:1801-6.
3. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153-8.
4. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 2009; 69:6660-7.
5. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-73.
6. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. Cosmic 2005. Br J Cancer 2006; 94:318-22.
7. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74.
8. Parsons DW, Jones S, Zhang X, Lin J, Leary RJ, Angenendt P, et al. An integrated genomic analysis of glioblastoma multiforme. Science 2008; 321:1807-12.
9. Amit Y, Geman D. Shape quantization and recognition with randomized trees. Neural Comput 1997; 9:1545-88. (Pubitemid 127462804)
10. Breiman L. Classification and regression trees Regression trees The Wadsworth statistics/probability series. Wadsworth International Group 1984.
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 289-300.
12. Bowers AJ, Boylan JF. Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene 2004; 328:135-42.
13. Kim MS, Radinger M, Gilfillan AM. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 2008; 29:493-501.
14. Ji H, Rintelen F, Waltzinger C, Bertschy Meier D, Bilancio A, Pearce W, et al. Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood 2007; 110:2940-7.
15. Ferguson GJ, Milne L, Kulkarni S, Sasaki T, Walker S, Andrews S, et al. PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol 2007; 9:86-91.
16. Thomas MS, Mitchell JS, DeNucci CC, Martin AL, Shimizu Y. The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J Leukoc Biol 2008; 84:814-23.
17. Sasaki T, Irie-Sasaki J, Horie Y, Bachmaier K, Fata JE, Li M, et al. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature 2000; 406:897-902.
18. Kratz CP, Emerling BM, Bonifas J, Wang W, Green ED, Le Beau MM, et al. Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood 2002; 99:372-4.
19. Semba S, Itoh N, Ito M, Youssef EM, Harada M, Moriya T, et al. Downregulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma. Clin Cancer Res 2002; 8:3824-31.
20. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine. Mol Cell 2000; 6:909-19.
21. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125:733-47.
22. Williams R, Berndt A, Miller S, Hon WC, Zhang X. Form and flexibility in phosphoinositide 3-kinases. Biochem Soc Trans 2009; 37:615-26.
23. Raben DM, Wattenberg BW. Signaling at the membrane interface by the DGK/SK enzyme family. J Lipid Res 2009; 50:35-9.
24. Baldanzi G, Mitola S, Cutrupi S, Filigheddu N, van Blitterswijk WJ, Sinigaglia F, et al. Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. Oncogene 2004; 23:4828-38.
25. Yanagisawa K, Yasuda S, Kai M, Imai S, Yamada K, Yamashita T, et al. Diacylglycerol kinase alpha suppresses tumor necrosis factor-alpha-induced apoptosis of human melanoma cells through NFkappaB activation. Biochim Biophys Acta 2007; 1771:462-74.
26. Bacchiocchi R, Baldanzi G, Carbonari D, Capomagi C, Colombo E, van Blitterswijk WJ, et al. Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. Blood 2005; 106:2175-82.
27. Mujica AO, Brauksiepe B, Saaler-Reinhardt S, Reuss S, Schmidt ER. Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men. Febs J 2005; 272:4884-98. (Pubitemid 41415113)
28. Downward J. Finding the weakness in cancer. N Engl J Med 2009; 361:922-4.
29. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137:821-34.
30. Nihira K, Taira N, Miki Y, Yoshida K. TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress. Oncogene 2008; 27:7285-95.
31. Cui Y, Guadagno TM. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene 2008; 27:3122-33.
32. Olesen SH, Thykjaer T, Orntoft TF. Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3 and TTK in human bladder cancer, screening for mutations and loss of heterozygosity. Carcinogenesis 2001; 22:813-5.
33. Geiges D, Meyer T, Marte B, Vanek M, Weissgerber G, Stabel S, et al. Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta and eta by tumor-promoting and nontumor-promoting agents. Biochem Pharmacol 1997; 53:865-75.
34. Verbeek DS, Goedhart J, Bruinsma L, Sinke RJ, Reits EA. PKCgamma mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. J Cell Sci 2008; 121:2339-49.
35. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11:9-22.
36. Otto EA, Trapp ML, Schultheiss UT, Helou J, Quarmby LM, Hildebrandt F. NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis. J Am Soc Nephrol 2008; 19:587-92. (Pubitemid 351355402)
37. Plotnikova OV, Pugacheva EN, Golemis EA. Primary cilia and the cell cycle. Methods Cell Biol 2009; 94:137-60.
38. Seeley ES, Carriere C, Goetze T, Longnecker DS, Korc M. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res 2009; 69:422-30.
39. Liu S, Lu W, Obara T, Kuida S, Lehoczky J, Dewar K, et al. A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish. Development 2002; 129:5839-46.
40. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities and common features with human disease. J Am Soc Nephrol 2006; 17:2821-31.
41. Sohara E, Luo Y, Zhang J, Manning DK, Beier DR, Zhou J. Nek8 regulates the expression and localization of polycystin-1 and polycystin-2. J Am Soc Nephrol 2008; 19:469-76. (Pubitemid 351355390)
42. Munster AK, Weinhold B, Gotza B, Muhlenhoff M, Frosch M, Gerardy-Schahn R. Nuclear localization signal of murine CMP-Neu5Ac synthetase includes residues required for both nuclear targeting and enzymatic activity. J Biol Chem 2002; 277:19688-96.
43. Cazet A, Julien S, Bobowski M, Krzewinski-Recchi MA, Harduin-Lepers A, Groux-Degroote S, et al. Consequences of the expression of sialylated antigens in breast cancer. Carbohydr Res 2010; (epub ahead of print).
44. Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai HH, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor. PLoS Genet 2009; 5:1000745.
45. Deng Q, Huang S. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene 2004; 23:4903-10. (Pubitemid 38932162)
46. Duan Z, Person RE, Lee HH, Huang S, Donadieu J, Badolato R, et al. Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5. Mol Cell Biol 2007; 27:6889-902.
47. Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M, et al. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 2007; 13:4786-94.
48. Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S. Expression of calbindin-D(28k) in a pancreatic islet beta-cell line protects against cytokine-induced apoptosis and necrosis. Endocrinology 2001; 142:3649-55. (Pubitemid 32681776)
49. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13:2061-7.
50. Robertson NG, Resendes BL, Lin JS, Lee C, Aster JC, Adams JC, et al. Inner ear localization of mRNA and protein products of COCH, mutated in the sensorineural deafness and vestibular disorder, DFNA9. Hum Mol Genet 2001; 10:2493-500.
51. Martina JA, Bonangelino CJ, Aguilar RC, Bonifacino JS. Stonin 2: an adaptor-like protein that interacts with components of the endocytic machinery. J Cell Biol 2001; 153:1111-20.
52. Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC, Boeckmann B, et al. The Universal Protein Resource (UniProt): an expanding universe of protein information. Nucleic Acids Res 2006 ;34(Database issue):D187-91.
53. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008; 3:157-88.
54. Hucl T, Rago C, Gallmeier E, Brody JR, Gorospe M, Kern SE. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 2008; 68:5023-30.